[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355898-105":59,"doc-detail-355898-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","eepd1-inhibition-unleashes-antitumor-immunity-in-colorectal-cancer-by-activating-the-cgas-sting-pathway","EEPD1 Inhibition Unleashes Antitumor Immunity in Colorectal Cancer by Activating the cGAS-STING Pathway","","Immunotherapy efficacy in colorectal cancer (CRC) is constrained by an immunosuppressive tumor microenvironment that prevents effective antigen presentation and T-cell function. This study identifies EEPD1, a gatekeeper of homologous recombination (HR) repair, as a driver of immune exclusion. EEPD1 downregulation disrupts HR, reduces proliferation and metastasis, and increases cytosolic DNA, activating the cGAS–STING/type I interferon axis. The resulting signaling matures dendritic cells, polarizes macrophages toward an inflammatory M1 state, boosts antigen presentation, and triggers CD8+ T-cell activation and cytotoxicity. Targeting EEPD1 sensitizes CRC to anti-PD1 therapy and may overcome checkpoint blockade resistance.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/eepd1-inhibition-unleashes-antitumor-immunity-in-colorectal-cancer-by-activating-the-cgas-sting-pathway/355898/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/eepd1-inhibition-unleashes-antitumor-immunity-in-colorectal-cancer-by-activating-the-cgas-sting-pathway/355898.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem limits immunotherapy effectiveness in colorectal cancer?","Question",{"text":112,"@type":113},"CRC immunotherapy is often limited by an immunosuppressive tumor microenvironment that reduces immunogenicity, including inadequate antigen presentation and impaired T-cell function, which hinders immune checkpoint blockade.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does EEPD1 inhibition affect CRC cells?",{"text":117,"@type":113},"EEPD1 downregulation compromises homologous recombination repair, increases genomic instability, impairs proliferation and metastatic capacities, and promotes cytosolic DNA accumulation in CRC cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune pathway is activated by EEPD1 deficiency?",{"text":121,"@type":113},"Cytosolic DNA accumulation activates the cGAS–STING axis, driving type I interferon signaling and downstream interferon-stimulated gene programs that support antitumor immune responses.",{"name":123,"@type":110,"acceptedAnswer":124},"How does EEPD1 targeting relate to anti-PD1 immunotherapy?",{"text":125,"@type":113},"The findings show a direct mechanism whereby targeting EEPD1 sensitizes colorectal cancer to anti-PD1 immunotherapy, potentially helping overcome resistance to immune checkpoint blockade.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},355898,1790168430,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nEEPD1 Inhibition Unleashes Antitumor Immunity in Colorectal Cancer by Activating the cGAS-STING Pathway  \nLiyun Huo1   Chong Wu1  Xiaobo Li2  Caina Ma3  Jiamin Huang4  Zishuo Chen5  Weiling He1, 6  Tianyu Tao7   Weijing Zhang8  \n1 Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China  2The Core Facilities for Medical Science at Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China  3 Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China  4 Department of Microbiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China  5 Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China  6 Department of Gastrointestinal Surgery, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China  7 Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China  8 Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China  \nCorrespondence: Weiling He ([wlhe@xah.xmu.edu.cn](wlhe@xah.xmu.edu.cn))  Tianyu Tao (Taoty@alumni.sysu.edu.cn)  Weijing Zhang (zhangwj@sysucc.org.cn)  \nReceived: 12 November 2025  Revised: 3 March 2026  Accepted: 24 March 2026  \nKeywords: antitumor immunity | cGAS-STING pathway | colorectal cancer | EEPD1 | immunotherapy  \nABSTRACT  \nThe efficacy of immunotherapy in colorectal cancer (CRC) is frequently limited by an immunosuppressive tumor microenvironment. Here, we identify exonuclease/endonuclease/phosphatase domain-containing protein 1 (EEPD1), a gatekeeper of homologous recombination (HR) repair, as a key driver of this immune exclusion. Downregulation of EEPD1 profoundly compromises HR in CRC cells, which curtails their proliferative and metastatic capacities in vitro and in vivo. Mechanistically, EEPD1 deficiency fuels genomic instability, leading to cytosolic DNA accumulation and activation of the cGAS-STING-type I interferon axis. This cascade promotes dendritic cell maturation, skews macrophages toward a proinflammatory M1 phenotype, and enhances tumor-associated antigen presentation, culminating in robust CD8+ T cell activation and cytotoxicity. Our findings elucidate a direct mechanism by which targeting EEPD1 sensitizes CRC to anti-PD1 immunotherapy. Our work establishes EEPD1 as a promising therapeutic target to overcome immune checkpoint blockade resistance in colorectal cancer.  \n1  Introduction  \nColorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, with a bleak prognosis for patients with advanced disease [1–3] . While targeted therapies and immunotherapy have modestly improved outcomes, their efficacy is often transient due to substantial tumor heterogeneity and a profoundly immunosuppressive tumor microenvironment (TME) [4–6]. A key feature of this TME is diminished immuno-  \ngenicity, characterized by inadequate antigen presentation and impaired T cell function, which presents a formidable barrier to effective immune checkpoint blockade (ICB) [7–9] .  \nGenomic instability is a fundamental hallmark of cancer that can, paradoxically, be exploited for therapeutic benefit [10–12] . The DNA damage response (DDR) network is essential for maintaining genomic integrity, and its inhibition represents a compelling anticancer strategy [13, 14]. Targeting DDR pathways  \n\n| Liyun Huo and Chong Wu contributed equally to this work.\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original w","cbCaid6FFr8kEhd2","https://ap.wps.com/l/cbCaid6FFr8kEhd2","pdf",14842637,"English","# Introduction\n## Tumor microenvironment and immune checkpoint blockade barriers\n## Genomic instability and DDR targeting\n## cGAS–STING activation by cytosolic DNA\n## Role of EEPD1 in HR repair and cancer immunity","[{\"question\":\"What problem limits immunotherapy effectiveness in colorectal cancer?\",\"answer\":\"CRC immunotherapy is often limited by an immunosuppressive tumor microenvironment that reduces immunogenicity, including inadequate antigen presentation and impaired T-cell function, which hinders immune checkpoint blockade.\"},{\"question\":\"How does EEPD1 inhibition affect CRC cells?\",\"answer\":\"EEPD1 downregulation compromises homologous recombination repair, increases genomic instability, impairs proliferation and metastatic capacities, and promotes cytosolic DNA accumulation in CRC cells.\"},{\"question\":\"What immune pathway is activated by EEPD1 deficiency?\",\"answer\":\"Cytosolic DNA accumulation activates the cGAS–STING axis, driving type I interferon signaling and downstream interferon-stimulated gene programs that support antitumor immune responses.\"},{\"question\":\"How does EEPD1 targeting relate to anti-PD1 immunotherapy?\",\"answer\":\"The findings show a direct mechanism whereby targeting EEPD1 sensitizes colorectal cancer to anti-PD1 immunotherapy, potentially helping overcome resistance to immune checkpoint blockade.\"}]","EEPD1 Inhibition Unleashes Antitumor Immunity in Colorectal Cancer by Activating the cGAS-STING Pathway | PDF",1790121619,48,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e516c9e78c62442dce430e0e78a03ae.webp",983,1283,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b83087fe378e017d15ed1c49359d595.webp",982,1281,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45ddc6cd423e189259f193195c6ebfd8.webp",981,1280,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c8cdf71d0b5d2f51790175a385c6f55.webp",980,1279]